Mapping Cerebellar Network Dysfunction in Episodic Ataxia Using Human Organoids
About the Project
This project investigates how mutations in the KCNA1 gene cause Episodic Ataxia Type 1 (EA1), a rare neurological disorder characterised by impaired motor coordination. Using patient-derived induced pluripotent stem cells (iPSCs), you will generate three-dimensional human cerebellar organoids to model early brain development and disease mechanisms. The research aims to determine how KCNA1 mutations disrupt neuronal differentiation, synaptic connectivity, and neural network function. Working…
within a multidisciplinary team specialising in advanced stem cell models of neurological disease, you will receive training in iPSC differentiation, organoid culture, and highresolution bioimaging while contributing to the development of future therapeutic strategies.
Introduction & Clinical Context: The cerebellum coordinates motor control, balance, and learning. Its dysfunction drives severe early-onset movement disorders, including ataxia, dystonia, and tremors. While genetic profiling has improved diagnosis, treatment remains restricted to symptom management. Progress is halted by an incomplete understanding of how mutations disrupt human brain development and neural network wiring. Because animal models fail to replicate human-specific cerebellar architecture, relevant human experimental systems are urgently needed to uncover underlying disease mechanisms.
The Challenge of Episodic Ataxia Type 1 (EA1): This project focuses on Episodic Ataxia Type 1 (EA1), a rare movement disorder caused by mutations in the KCNA1 gene, which encodes the Kv1.1 voltage-gated potassium channel. Kv1.1 channels regulate neuronal excitability and the precise timing of electrical signals. EA1 patients suffer from childhood-onset attacks of incoordination, balance loss, and muscle twitching. Crucially, EA1 exhibits extreme clinical heterogeneity; individuals with identical mutations—even within the same family—display widely differing symptom severities. This divergence suggests that complex, secondary neurodevelopmental and circuit-level factors drive disease progression beyond the initial channel defect.
Central Hypothesis & Model System: The central hypothesis is that KCNA1 mutations disrupt the development and maturation of inhibitory cerebellar microcircuits, causing a chronic imbalance between excitation and inhibition, abnormal neuronal synchrony, and loss of motor control. To investigate this without the limitations of animal models, the project utilizes patient-derived induced pluripotent stem cells (iPSCs) to generate 3D human cerebellar organoids. These "mini-brains" self-organize to produce human Purkinje neurons, granule cells, and inhibitory interneurons that form active synapses and generate spontaneous network activity, offering an unprecedented window into human neurodevelopment.
Research Objectives: Define Developmental & Circuit Pathology: The student will map celltype composition and growth trajectories in KCNA1-mutant organoids using high-resolution confocal imaging and single-cell profiling. Quantify Network Dysfunction: Using multi-electrode arrays (MEAs) and live-cell calcium imaging, the student will track real-time electrical communication, population synchrony, and synaptic stability. This will be paired with quantitative proteomics to pinpoint dysregulated molecular pathways.
Evaluate Targeted Therapies: The project will utilize the organoids as a precision medicine drug-screening platform. The student will test clinically approved drugs (e.g., carbamazepine) alongside novel KCNA1modulating molecules to identify strategies that rescue network stability.
Training & Environment: The student will receive elite, multi-disciplinary training spanning stem cell culture, organoid engineering, advanced electrophysiology, proteomics, and translational drug discovery. Embedded within a highly collaborative network of clinicians and neuroscientists, this project will uncover the fundamental mechanisms of EA1 and pioneer new therapeutic models for complex movement disorders.
A full description of the project can be found on the GW4 BioMed website.
Academic criteria: Applicants for a studentship must have obtained, or be about to obtain, a first or upper second-class UK honours degree, or the equivalent qualification gained outside the UK.
English requirements: IELTS with an overall score of 6.5 with 5.5 in all subskills, or acceptable alternative. Please see our English Language Requirements guidance for more details.
How to Apply
A list of all the projects and how to apply is available on the GW4 BioMed website. You may select up to 2 projects and submit one application per candidate only.
Please complete an application to the GW4 BioMed3 for an ‘offer of funding’. If successful, you will also need to make an application for an 'offer to study' to your chosen institution later.
Please note that we may close the application process before the stated deadline if an unprecedented number of applications are received– check the GW4 BioMed website for details and updates.
If you are shortlisted for interview, you will be notified from Tuesday, 22nd December 2026. Interviews will be held virtually on 26th and 27th January 2027. Studentships will start on 1st October 2027.
Funding Notes
These studentships are funded through GW4 BioMed3 MRC Doctoral Landscape Programme and consist of UK tuition fees, as well as a Doctoral Stipend matching UK Research Council National Minimum (£21, 805 p.a. for 2026/27, updated each year).
Additional research training and support funding of up to £5,000 per annum is also available.
GW4 BioMed3 studentships are available to UK and International applicants
This is a Preview Listing…
You must sign in to see the full job description, and to apply.
Manage / Upgrade this job to a Full Job Listing.
Find Your Best Opportunity
Tell them AcademicJobs.com sent you!